drugset / Trial / NCT06906224

Effects of Buspirone Combined With Clozapine

NCT06906224

RandomizedParallel-groupDouble-blindTreatment

Summary

This study aimed to evaluate the enhancing effects of different doses of buspirone on psychiatric symptoms and cognitive function in patients with schizophrenia. The investigators adopted a prospective, randomised, double-blind, placebo-controlled study design and included 46 patients with schizophrenia being treated at the Fourth People's Hospital of Wuhu. The patients were randomly divided into three groups: the control group, the low-dose group and the high-dose group. The control group received clozapine monotherapy, while the experimental groups received additional buspirone at different doses in addition to clozapine. The Positive and Negative Syndrome Scale (PANSS) and the Chinese version of the Repeatable Battery for the Assessment of Neuropsychological Status were used to evaluate psychiatric symptoms and cognitive function.

Timeline

Start
2022-05-01
Primary completion
2023-11-10
Completion
2023-12-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Buspirone Small molecule 15 mg Oral
Comparator Buspirone Small molecule 30 mg Oral
Comparator Clozapine Other / unclassified Oral

Indications